Biomea Fusion, Inc. (BMEA)

Market Cap	159.23M
Revenue (ttm)	n/a
Net Income (ttm)	-127.27M
Shares Out	35.94M
EPS (ttm)	-3.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	699,038
Open	4.410
Previous Close	4.420
Day's Range	4.350 - 4.681
52-Week Range	3.610 - 23.920
Beta	-0.37
Analysts	Buy
Price Target	26.63 (+501.13%)
Earnings Date	Jul 29, 2024

About BMEA

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: BMEA

Analyst Forecast

According to 10 analysts, the average rating for BMEA stock is "Buy." The 12-month stock price forecast is $26.63, which is an increase of 501.13% from the latest price.

Price Target

$26.63

(501.13% upside)

Analyst Consensus: Buy